{
    "nct_id": "NCT06561685",
    "official_title": "An Open-label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies With SMARCA4/BRG1 Alterations",
    "inclusion_criteria": "* Have one of the following locally advanced or metastatic solid tumor malignancy with SMARCA4 (BRG1) alteration:\n\n  * Phase 1a dose escalation: Presence of any alteration in SMARCA4 (BRG1)\n  * Phase 1b expansion: Part A: Non-small Cell Lung Cancer (NSCLC) that is locally advanced and not suitable for definitive locoregional therapy, or metastatic with presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.\n  * Phase 1b expansion: Part B: Any tumor type (other than NSCLC) that has the presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.\n* Prior Systemic Therapy Criteria:\n\n  * Phase 1a dose escalation and Phase 1b (Part B): Participants who received all standard therapies for which the individual was deemed to be an appropriate candidate by the treating Investigator; or the individual is refusing the remaining most appropriate standard of care treatment; or there is no standard therapy available for the disease.\n  * Phase 1b expansion (Part A): Participants must have received at least one line of therapy for advanced or metastatic disease.\n* Measurability of disease\n\n  * Phase 1a dose escalation (excluding backfill): measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)\n  * Phase 1a backfill and Phase 1b expansion: Measurable disease required as defined by RECIST v1.1\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants with known loss of function alteration of SMARCA2 (BRM) or malignancy with known association with SMARCA2 (BRM) alterations\n* Prior exposure to SMARCA2 (BRM) inhibitor(s) and/or degrader(s) (prior exposure may be permitted for dose escalation)\n* Participants with known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement\n* Participants with history of increased risk of prolonged QT or significant arrythmia\n* Significant cardiovascular disease\n* Participants with active or recently treated (within 2 years) second primary malignancy and/or treated for an additional malignancy within 2 years prior to enrolment\n* Participants who are pregnant, breastfeeding or plan to breastfeed or expecting to conceive or father children during study or within 6 months after the last dose of study intervention",
    "miscellaneous_criteria": ""
}